KLK3 and posterior cortical atrophy: By contrast however, targeting Hsp27 has shown promise in PCa clinical trials in combination with prednisone in patients with metastatic CRPC; up to 71% of patients were progression free at 12 weeks and 50% showed 50% reduction in PSA when treated with the Hsp27 antisense OGX-427 and prednisone [129].